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Abstract
Introduction: Glioblastoma with oligodendroglioma component (GBM-O) was recognized as a histologic pattern of
glioblastoma (GBM) by the World Health Organization (WHO) in 2007 and is distinguished by the presence of
oligodendroglioma-like differentiation. To better understand the genetic underpinnings of this morphologic entity,
we performed a genome-wide, integrated copy number, mutational and transcriptomic analysis of eight (seven
primary, one secondary) cases.
Results: Three GBM-O samples had IDH1 (p.R132H) mutations; two of these also demonstrated 1p/19q co-deletion
and had a proneural transcriptional profile, a molecular signature characteristic of oligodendroglioma. The
additional IDH1 mutant tumor lacked 1p/19q co-deletion, harbored a TP53 mutation, and overall, demonstrated
features most consistent with IDH mutant (secondary) GBM. Finally, five tumors were IDH wild-type (IDHwt) and had
chromosome seven gains, chromosome 10 losses, and homozygous 9p deletions (CDKN2A), alterations typical of
IDHwt (primary) GBM. IDHwt GBM-Os also demonstrated EGFR and PDGFRA amplifications, which correlated with
classical and proneural expression subtypes, respectively.
Conclusions: Our findings demonstrate that GBM-O is composed of three discrete molecular subgroups with
characteristic mutations, copy number alterations and gene expression patterns. Despite displaying areas that
morphologically resemble oligodendroglioma, the current results indicate that morphologically defined GBM-O
does not correspond to a particular genetic signature, but rather represents a collection of genetically dissimilar
entities. Ancillary testing, especially for IDH and 1p/19q, should be used for determining these molecular subtypes.
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Introduction
Glioblastoma (GBM) is the highest grade infiltrating as-
trocytoma and the World Health Organization (WHO)
recognizes several morphologic patterns. Glioblastoma
with Oligodendroglioma component (GBM-O), WHO
grade IV, was recently described as a diffusely infiltrative,
high-grade astrocytic neoplasm displaying necrosis, and
also demonstrating discrete areas of oligodendroglial dif-
ferentiation [1]. Some studies have suggested that
oligodendroglioma-like areas in GBM may confer a fa-
vorable prognosis, yet this remains controversial [2–8].
Moreover, it is unclear whether GBM-O represents a dis-
tinct entity with defining molecular alterations and clinical
behavior or a collection of genomically disparate tumors
containing similar morphologic elements [2–6, 8, 9].
Prior studies suggested that GBM-O is enriched for
IDH mutations and has fewer PTEN deletions than other
forms of GBM [2]. Co-deletion of chromosomes 1p and
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19q is the molecular signature of oligodendroglioma and
associated with enhanced therapeutic response and lon-
ger survival [10], yet most studies of GBM-O have iden-
tified 1p/19q co-deletion only in a modest subset [6, 8].
Conversely, EGFR amplifications, which are mutually ex-
clusive from IDH mutations and 1p/19q co-deletions,
have been documented in GBM-Os and may define a
clinically relevant subset [3]. Advanced whole genome
molecular platforms can provide additional biologic
insights into tumor subtypes, above that offered by
morphology or a limited biomarker panel [4, 11, 12].
Therefore, in order to better characterize GBM-O, we
performed copy number microarray, whole transcriptome
RNA-sequencing and gene panel deep sequencing.
Materials and methods
Patient information and histopathology
All tumor tissue was obtained from patients who under-
went surgical resection and pathological evaluation at
Emory University Hospitals from 2007 through 2011.
Two neuropathologists reviewed all hematoxylin and
eosin (H&E)-stained slides from each case concurrently
using a multi-headed microscope. GBM-O was the ori-
ginal pathologic diagnosis in all cases, and all diagnoses
were rendered using World Health Organization 2007
criteria [1]. Paraffin embedded tissue sections of 10-
micron thickness were macro-dissected to maximize vi-
able tumor submitted for genomic analysis. Six of eight
samples contained >95 % viable tumor, while a single
case each contained significant necrosis or normal tissue
(25 %, case 8; 40 %, case 5, respectively). In all cases,
submitted tissue included regions of oligodendroglial dif-
ferentiation (Fig. 1). Summary clinical data and molecu-
lar/cytogenetic testing results are shown in Fig. 2a. FISH
testing (EGFR, 1p/19q) and mutant IDH1 expression by
immunohistochemistry, were previously performed as
described [2]. Immunohistochemistry for ATRX (1:100;
Sigma-Aldrich Corp., St. Louis, MO, USA) assessed nu-
clear expression in select cases.
Nucleic acid isolation and QC
Serial sections were evaluated for tumor proportion and
necrosis prior to nucleic acid extraction. DNA and RNA
were extracted using the QIAGEN (Valencia, CA) All-
Prep FFPE kit. Genomic DNA was quantitated using the
Fig. 1 Photomicrographs of GBM-O cases. Images show representative areas of macrodissected tumor (H&E, 20×). In all cases, submitted tissue
included regions of oligodendroglial differentiation
Fig. 2 Clinicopathologic features of GBM-O cases and results of targeted
Fluidigm DNA sequencing. a Case details including previously obtained
FISH (EGFR, 1p/19q) and IDH1 R132H immunohistochemistry results.
*prior diagnosis was fibrillary astrocytoma, grade II b Nonsynonymous
mutations were detected in 5/8 cases (12 missense, 1 nonsense).
Numerals in boxes indicate number of mutations if more than one
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Qubit dsDNA high sensitivity (HS) kit (ThermoFisher
Scientific, Waltham, MA); total RNA was quantitated
and quality checked using the Agilent 2100 Bioanalyzer
with the RNA 6000 pico kit (Agilent Technologies, Santa
Clara, CA).
Targeted amplicon DNA sequencing
A custom amplicon-library preparation assay was devel-
oped for the Fluidigm Access Array (Fluidigm Corpor-
ation, South San Francisco, CA) using the D3 Assay
Design software. Coding exons of 12 genes previously
reported as recurrently mutated in GBM were targeted
(BRAF, EGFR, IDH1, IDH2, NF1, NRAS, PDGFRA,
PIK3CA, PIK3R1, PTEN, RB1, TP53) [13] (Additional file
1: Table S1). Briefly, the Bioinformatic variant/indel (col-
lectively referred to as “variants”) pipeline comprised
trimming low quality bases and adapters using Trimmo-
matic 0.32 [14]; merging overlapping paired end reads
with ea-utils fastq-join version 1.1.2-686 (https://code.-
google.com/p/ea-utils/), and keeping the highest quality
base call from the overlapping region; alignment to the
hg19 human reference genome using the BWA-mem
aligner version 0.7.5a [15]; calling potential variants with
VarScan2 requiring at least 20× coverage, five non-
reference reads with a minimum base quality score of 20
and a minimum variant allele frequency of 0.25 [16].
Predicted variants were annotated with ANNOVAR [17]
(Additional file 2: Table S2). Since we used archival FFPE
tissue without matched normal DNA, we carried out ex-
tensive filtering of predicted variants and manually veri-
fied variants using Integrative Genomics Viewer [18].
Variants not present in the Catalogue of Somatic Muta-
tions in Cancer (COSMIC) database were required to
have 1,000× coverage [19, 20]. Likely germline variants
that were observed at greater than 1 % frequency in ei-
ther the Thousand Genomes Project or Exome Variant
Server were filtered out [21, 22]. Those found in dbSNP
without previously being linked to cancer were also re-
moved [23].
Copy number microarray
Extraction and hybridization of genomic DNA to Illu-
mina HumanCytoSNP-12v2.1-FFPE SNP arrays was ac-
cording to manufacturer’s instructions. Data were
processed and analyzed with BioDiscovery Nexus soft-
ware (Hawthorne, CA) using SNPRank segmentation
and a segmented log2 ratio of 0.09 to call gains, 0.3 for
amplifications, -0.135 for losses and -0.45 for homozy-
gous deletions. Combined segmented data was viewed
using Copy Number Explorer software [24].
Whole transcriptome sequencing
RNAseq library preparation and Illumina HiSeq sequen-
cing were carried out by Beckman Coulter Genomics
(Danvers, MA) using Illumina TruSeq RNA library prep-
aration and HiSeq2500 sequencing. RNA sequencing pro-
duced approximately 50 million reads per sample. We
aligned paired-end fastq files to the hg19 human reference
genome using Tophat 2.0.6 under standard parameters
[25]. RefSeq Transcripts were quantified and transformed
into FPKM values using Cufflinks 2.02 [26].
Gene expression-based molecular classification
We used TCGA GBM samples to derive an RNASeq
gene list with which to classify our GBM-O samples. 164
TCGA samples had been classified into one of four sub-
groups based on expression microarray profiles and also
had accompanying RNA-Seq data [13]. We initially per-
formed non-negative matrix factorization consensus
clustering with a k-value of four using gene pattern soft-
ware [27] and the NMF module. We omitted samples
whose NMF cluster and microarray expression subclass
were discordant, leaving 115 samples. We used shrunken
centroids, deployed through the pamr R-package to
identify the gene sets that best classified each subtype
[28]. The best-performing classification sets were a subset
of the original 840-gene classifier described by Verhaak et
al. [29] and comprised of 129 genes specific to classical,
160 messenchymal, 65 neural and 131 proneural genes
(Additional file 3: Table S3). We used Gene Set Variation
Analysis (GSVA) [30], an enhanced version of Single Sam-
ple Gene Set Enrichment Analysis (ssGSEA) [31], to clas-
sify expression microarray profiles from TCGA patient
samples. GSVA classified 94 % of samples correctly (as
assessed by cluster membership based on GSVA score)
(not shown). We deployed GSVA through the GSVA R-
package [30], to our GBM-O samples.
Results
Clinicopathologic features of GBM-O
From January, 2008 through December, 2011, we made
the diagnosis of GBM-O 28 times. Eight of these cases
were chosen based on availability of tissue and diversity of
clinical diagnostic markers. Of these, seven were primary
and one secondary (case 1), the latter having been diag-
nosed as a fibrillary astrocytoma, grade II four years prior.
Ages at diagnosis ranged from 29- to 78-years (mean, 55-
years) and clinical follow-up revealed patient survivals
ranged from 2- to 69-months (mean, 23 months; median,
17.5 months). Tumors were classified as GBM-O if a
discrete area of oligodendroglial differentiation (occupying
at least a single 100× microscopic field) occurred in the
setting of a high-grade astrocytic neoplasm with necrosis
[2]. Oligodendroglial differentiation was recognized as gli-
oma cells containing round, regular nuclei with only mild
variation accompanied by a delicate capillary vascular net-
work and occasionally by cytoplasmic clearing [32]. Alter-
natively, high-grade astrocytic differentiation was defined
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as glioma cells with elongated, hyperchromatic nuclei and
irregular nuclear contours [32]. Photomicrographs in Fig. 1
show representative areas of tumor analyzed for each case.
Previous diagnostic testing included FISH analysis of
EGFR and 1p and 19q as well as immunohistochemistry
for IDH1 p.R132H (Fig. 2a). Cases harboring different
combinations of genetic alterations were chosen to cap-
ture the molecular diversity displayed in GBM-O. Two
were positive for mutant IDH1 protein and had 1p/19q
co-deletions and were negative for EGFR amplification.
Four cases were EGFR-amplified and did not show mu-
tant IDH1 protein expression or 1p/19q co-deletion; an
additional case was EGFR-amplified, IDH1 wild-type and
had a 1p deletion. The remaining case did not show any
molecular alteration detected by FISH or IHC staining.
Of note, the presence of 1p/19q co-deletion did not correlate
with higher percentages of oligodendroglioma component.
Detection of coding variants using targeted Fluidigm
DNA sequencing
We performed DNA sequencing to identify coding vari-
ants in 12 genes recurrently mutated in GBM (BRAF,
EGFR, IDH1, IDH2, NF1, NRAS, PDGFRA, PIK3CA,
PIK3R1, PTEN, RB1, TP53) [13] (Fig. 2b, Additional file 2:
Table S2). In agreement with IHC results, cases 1 and 2
displayed IDH1 (c.395G > A; p.R132H) mutations. Case 2,
which was 1p/19q co-deleted, also contained a PIK3CA
mutation, concordant with previous studies showing cor-
relation among these alterations [11]. Additionally, case 3
also had an p.R132H mutation, despite being reported as
negative by R132H IHC [33, 34], as well as a TP53 muta-
tion (c.481G > A, p.A161T) that has been previously re-
ported in diffuse gliomas (COSM10739). The co-
occurrence of TP53 and IDH mutations is seen in the
large majority of lower-grade (WHO grades II-III) diffuse
astrocytomas, as well as secondary GBMs (WHO grade
IV) and defines a lineage of IDH mutated tumors distinct
from 1p/19q co-deleted oligodendrogliomas [11, 34]. Al-
though ATRX alterations are frequently seen together with
IDH and TP53 mutations, we did not demonstrate loss of
ATRX expression by IHC in this case [35, 36].
The remaining five cases were all IDH wild-type
(IDHwt). EGFR and PDGFRA mutations were noted ex-
clusively in IDHwt GBM-Os and all NF1 mutations were
also noted in this subset. EGFR and PDGFRA mutations
were both seen in the context of EGFR and PDGFRA
amplification respectively (see below), an association
previously observed in primary GBM [29].
Copy number microarray
Detection of specific somatically-acquired copy-number
aberrations (CNAs) aids in CNS tumor classification,
and may provide important insight into tumor biology
[29]. To determine if GBM-O displayed distinct patterns
of CNA, we performed copy number microarray ana-
lysis. While FISH is used diagnostically to assess CNAs
at defined loci (EGFR, PTEN and 1p/19q) microarray
testing can detect copy number changes genome wide. A
full list of copy number segments is in Additional file 4:
Table S4.
There was general agreement between microarray and
diagnostic FISH testing (Fig. 3): Cases 1 and 2 showed
1p/19q deletion by both FISH and microarray. Case 3
was negative by FISH and microarray for 1p/19q dele-
tion and EGFR amplification. Cases 4, 5, 7 and 8 were
EGFR amplified by both FISH and microarray. Case 6
was EGFR amplified by FISH, but the reported percent-
age of cells showing amplification (28/200, 14 %) was
below our detection threshold of approximately 30 % for
this microarray. Case 5 demonstrated 1p deletion and
19q gain by FISH. Microarray showed a gain of chromo-
some 19, but no loss of 1p. Reanalysis with a more sensi-
tive segmentation algorithm, ASCAT [37, 38] (data not
shown) identified a terminal 55 Mb deletion of 1p. These
results are consistent and rule out a whole arm loss of
chromosome 1.
Gains, losses and amplifications of other loci were evi-
dent but there was no single CNA found across all cases;
rather, three general patterns were apparent: One group
(cases 1 and 2) had 1p/19q co-deletion, and lacked gains
of chromosome 7, amplifications of EGFR or losses of
chromosome 10. Another group (cases 4, 5, 6, 7, and 8)
demonstrated either broad gains of chromosome 7 or
focal amplifications of 7p11.2 including EGFR, and most
showed loss of chromosome 10 (including PTEN) as well
as heterozygous deletion of 9p with or without focal
homozygous deletion of CDKN2A. Several of these cases
also had other CNAs previously described in GBM but
not oligodendroglioma including PDGFRA amplification
(cases 5 and 6) and MDM2 amplification (case 4) [13].
Lastly, case 3 displayed a third pattern of copy number
alteration. While showing alterations overlapping those
seen in the latter group (gain of chromosome 7 and het-
erozygous deletion of 9p), case 3 also demonstrated al-
terations not present in other cases including loss of
chromosome 3 and 9q, as well as gains of 16p and chro-
mosomes 5 and 21.
Gene expression-based molecular classification
Previous gene expression studies identified four GBM
expression subtypes - proneural, classical, neural and
mesenchymal - named after the expression signature’s
resemblance to transcriptional profiles of neural cell
types [29]. We next determined if our GBM-O samples
were all classified as the same expression subgroup or,
alternatively, represented a combination of two or more
subgroups. We performed RNASeq gene expression pro-
filing and classified these data using Gene Set Variation
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Analysis (GSVA). GSVA expression enrichment scores
for GBM-O cases are displayed in Fig. 4. A column Z-
score of >0.5 was used as a cutoff to determine whether
a tumor sample was enriched for a particular subtype
expression signature. Additional file 5: Figure S1 displays
nominal scores indicating correlation between sample
transcriptional profile and expression subtype compared
across samples. Expression values for select genes are
provided in Additional file 6: Table S5.
Overall, all four GBM expression subtypes were rep-
resented among the eight GBM-Os (Fig. 4). Five dem-
onstrated expression signatures strongly enriched for
one subtype, while the remaining three had transcrip-
tional profiles enriched for two subtypes (Fig. 4 and
Additional file 5: Figure S1). Three tumors showed ex-
clusive classification as the proneural subtype (cases 1,
2, and 6), and one tumor each was classified exclusively
as classical and mesenchymal (cases 7 and 3,
respectively). Cases 4 and 5 showed enrichment for
both classical and neural genes, while case 8 showed
both mesenchymal and neural signatures.
The three tumor samples classified as proneural were
tightly clustered and included two of three IDH1 mutant
tumor samples, consistent with other studies demon-
strating this strong association [3, 29]. Also in concord-
ance with previous studies, all cases demonstrating
proneural gene expression signatures showed increased
expression levels of the proneural gene DCX [29]. An
additional GBM-O with proneural expression profile ex-
hibited high-level PDGFRA amplification and gene ex-
pression, also typical of this transcriptional subtype [29].
Cases with classical signatures demonstrated substan-
tially elevated EGFR expression, a discriminating feature
of this subtype [29]. Consistent with previous reports,
tumor samples in the classical subgroup also demon-
strated increased expression of LFNG, a gene encoding for
an O-fucosylpeptide 3-beta-N-acetylglucosaminyltransfer-
ase known to affect Notch signaling [29].
Two cases showed enrichment for the mesenchymal
gene set and both demonstrated increased expression of
CHI3L1, a marker consistently elevated in this subtype
[39]. RELB and TNFRSF1A, genes involved in the NF-kB
and tumor necrosis factor super family pathways, were also
elevated, consistent with prior reports [29]. One of the
GBM-Os classified as mesenchymal (case 8) demonstrated
Fig. 3 Patterns of recurrent copy-number aberrations (CNAs) identified using Illumina microarray. Focal amplifications of 7p11.2 (EGFR) and gains
of chr7 were present in 4/8 and 6/8 cases, respectively, and were mutually exclusive of 1p/19q co-deletion and IDH1 R132H mutation (cases 1 and 2).
Loss of chr10 (PTEN) and homozygous 9p21.3 loss (CDKN2A) occurred in 4/4 and 2/4 cases with EGFR amplification, respectively. Focal gains involving
4q12 (PDGFRA) were present in 2 cases
Fig. 4 Gene expression profile heat map. A positive enrichment score
(column Z-score) indicates the tumor sample expression profile and
the genes in that particular gene set are positively correlated, whereas
a negative enrichment score indicates the opposite. Five tumors
demonstrated expression signatures enriched for one subtype,
while the remaining three had transcriptional profiles enriched for
two. Three tumors showed exclusive classification as the proneural
subtype (cases 1, 2, and 6), and one tumor each was classified
exclusively as classical and mesenchymal (cases 7 and 3, respectively).
Cases 4 and 5 showed both classical and neural signatures, while case
8 showed both mesenchymal and neural subtype expression patterns
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a significant percentage of necrosis (25 %), a feature ob-
served in mesenchymal GBMs in the TCGA cohort [29].
Three GBM-O samples demonstrated enrichment for
neural gene sets and two of the three showed substan-
tially elevated expression of the neuron marker SYT1 in
concordance with previous studies [29]. Although two
normal brain tissue samples analyzed by Verhaak et al.
[29] were categorized as the neural subtype, only one of
the three current tumor samples contained a significant
percentage of benign tissue (case 5).
Integration of molecular platforms
Previous studies of GBM have shown associations be-
tween transcriptional signatures, somatic mutations and
DNA copy number alterations [3, 29]. To investigate
whether these associations are also present in GBM-O,
we correlated patterns of somatic mutation and DNA
copy number alterations with expression subtype (Fig. 5).
Overall, the selected GBM-Os could be divided into
three groups. The first (cases 1 and 2) consisted of
GBM-Os with IDH1 mutations and 1p/19q co-deletions
and lacked DNA copy number alterations typical of
GBM such as EGFR amplification, gains of chromosome
7 and losses of 10 [13]. IDH1 mutations and 1p/19q co-
deletion have been shown to be strongly correlated in
GBM-O [2, 40]. Case 2 also contained a PIK3CA muta-
tion, a finding previously documented with IDH muta-
tions and 1p/19q co-deletion [11]. Both IDH1 mutant,
1p/19q co-deleted tumors showed a proneural gene
expression signature, and, therefore, displayed genetic al-
terations resembling those seen in oligodendrogliomas
[34].
An additional tumor (case 3) was IDH1 mutated, but
lacked 1p/19q co-deletion and harbored a TP53 muta-
tion. This genetic pattern is typical of IDH mutant dif-
fuse atrocytomas of WHO grades II, III and IV [41].
While this case showed additional characteristics of
astrocytic lineage, including gain of chromosome 7 and
heterozygous deletion of 9p, it lacked typical alterations
of primary GBM such as EGFR amplification, chromo-
some 10 loss and homozygous deletion of CDKN2A.
Taken together, these findings are most consistent with
an IDH mutant GBM, often referred to clinically as “sec-
ondary” GBM.
The remaining 5 GBM-Os were IDH wild-type (IDHwt).
Four of the IDHwt tumors were amplified for EGFR (cases
4, 5, 7 and 8), had broad gains of chromosome 7, loss of
chromosome 10, CDKN2A deletion (two cases) and
showed enrichment for the classical expression gene sets
(three cases). Among cases with classical transcription sig-
natures, high-level EGFR amplification corresponded to
significantly elevated EGFR expression. The GBM-O that
harbored an EGFR mutation also showed EGFR amplifica-
tion and had a classical expression signature.
One of the IDHwt tumors (case 6) demonstrated a
proneural expression signature and exhibited the charac-
teristic constellation of 4q12 focal amplification involv-
ing PDGFRA, high levels of PDGFRA gene expression,
as well as PDGFRA mutation. This case also demon-
strated chromosome 7 gain and losses of 10 and 9p, in-
dicating additional copy number similarity with primary
GBM.
Among IDHwt tumors, transcriptional profiles were
predominantly classified as classical and neural; however,
this subgroup also contained representatives from the
proneural and mesenchymal subtypes. IDHwt GBM-Os
in the current study, therefore, displayed gene expres-
sion diversity similar to GBMs in the TCGA cohort [29].
Coupled with the classic DNA copy-number alterations
discussed above, the IDHwt subgroup overall demon-
strated molecular alterations most consistent with pri-
mary GBM.
Conclusions
Glioblastoma with Oligodendroglioma component (GBM-
O) was introduced by the WHO classification in 2007 as
one of the morphologic patterns of GBM [1]. Clinical out-
comes data and biomarker profiles have, however, yielded
inconsistent results and the clinical significance and biol-
ogy of GBM-O is not well understood. While morphology
has informed CNS tumor classification for decades, mo-
lecular testing can also define distinct genetic entities with
specific clinical outcomes. Therefore, we employed copy
Fig. 5 Overview of molecular aberrations in GBM-O cases. Each column
represents a single case and cases are grouped by expression signature
subtype. In regards to EGFR and PDGFRA alterations, red boxes
indicate samples demonstrated both DNA amplification and
high-level gene expression, whereas samples with dark grey boxes
showed only amplification. Light grey boxes indicate negative for
mutation or balanced chromosomal status
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number microarray, whole transcriptome RNA-
Sequencing and gene panel deep sequencing to better
characterize the GBM-O entity. Our results showed that
despite having overlapping morphologic features, our
GBM-O cohort was composed of three discrete molecular
subgroups, each with characteristic coding variants, CNAs
and gene expression patterns.
Previous investigations have also attempted to clarify
the significance of GBM-O through molecular testing.
The presence of 1p/19q co-deletions has received particu-
lar attention given its association with oligodendrogliomas
and improved clinical outcomes [41]; however, reported
frequencies having ranged from 4 to 30 % [2–6, 8]. Com-
pared with conventional GBM, GBM-Os show consist-
ently increased frequencies of IDH1 mutations, though
enrichment of GBM-O cohorts with secondary GBMs
may explain this finding [2, 3, 8]. Despite the evidence for
an increased association between GBM-O and IDH muta-
tions and 1p/19q co-deletions, there is variation in clinical
outcome studies with some showing a favorable prognosis
when compared to conventional GBMs [2, 6–8, 42], while
others do not [3–5]. Lastly, investigations show wide-
ranging frequencies of EGFR amplification (39–71 %) as
well as LOH of 10q (0–58 %) highlighting the molecular
heterogeneity seen in GBM-O [2, 3, 6, 42]. Our current
data indicates that the variations in clinical outcomes and
biomarker status reported in these investigations may be
due to the inclusion of multiple molecular genetic entities
with overlapping morphologic features into the analyses.
While additional molecular variation could potentially
exist in the setting of morphologic diversity, previous data
has indicated genomic stability across morphologic
phenotypes [5].
A crucial subdivision of diffuse gliomas is based on IDH
mutational status, since IDH mutant tumors progress
more slowly and are associated with prolonged survival,
grade for grade [11, 34]. The large majority of grades II
and III diffuse gliomas, including oligodendrogliomas and
astrocytomas, are IDH mutant [11]. Only a small minority
of GBMs are IDH mutant and many of these have pro-
gressed from grade II and III astrocytomas (secondary
GBMs) [13]. In our analysis, three of eight GBM-Os were
IDH mutant, whereas five were IDHwt. Two of the IDH
mutant tumors in our cohort were 1p/19q co-deleted re-
capitulating the strong positive correlation between these
alterations seen in other studies of GBM-O [2, 9, 40].
These tumors also had a proneural transcriptional profile,
and therefore, overall demonstrated a molecular signature
that is classic for oligodendroglioma. Both patients with
this molecular signature had survivals (20 and 41 months)
longer than the median for this cohort (17.5 months). In-
tegrating the genetic findings of these high grade gliomas
with IDH mutations and 1p/19q co-deletions, as suggested
by a recent international consensus of neuropathologists,
would lead to their categorization as anaplastic oligo-
dendroglioma, WHO grade III, with IDH mutation and
1p/19q co-deletion, rather than GBM-O [43].
An additional tumor (case 3) was IDH1 mutated, but
it lacked 1p/19q co-deletion and harbored a TP53 muta-
tion. The constellation of IDH1 and TP53 mutation
without 1p/19q co-deletion is seen in diffuse astrocyto-
mas of WHO grade II, III and IV [11, 41]. Interestingly,
the occurrence of a TP53 mutation in the context of an
intact 1p arm as in this case, is consistent with the mu-
tual exclusivity of 1p deletion and p53 overexpression
observed in other GBM-O cohorts [2, 9]. Typical alter-
ations seen in IDHwt (primary) GBM such as EGFR
amplification, chromosome 10 loss and homozygous de-
letion of CDKN2A were not present, although the ob-
served gain of chromosome 7 and heterozygous deletion
of 9p provide further evidence of the tumor’s astrocytic
lineage. Overall, the identified IDH1 and TP53 muta-
tions, the lack of molecular alterations seen in primary
GBM and the longest survival of the study indicate this
case is an IDH mutant form of GBM, often referred to
as “secondary GBM”.
IDH wild-type GBM-Os in our cohort, on the other
hand, were characterized by chromosome 7 gains, chromo-
some 10 losses, and 9p (CDKN2A) deletions; signatures of
an astrocytoma lineage and most typical of IDHwt GBM
[29, 41]. This subgroup contained additional alterations
characteristic of IDHwt GBM such as EGFR amplification
and mutation, as well as NF1 mutations. EGFR amplified
tumors were mostly associated with the classical transcrip-
tional class, as previously described [29]. IDHwt GBM-Os
also contained representatives from the proneural, mesen-
chymal, and neural subtypes and, therefore, display diver-
sity homologous to GBMs in the TCGA cohort [29]. In
addition, we also identified an IDHwt GBM-O with high
level PDGFRA amplification and a gene expression profile
aligned with the proneural class, an association also previ-
ously established in primary GBM [29]. Lastly, consistent
with behavior of tumors molecularly resembling primary
GBM, all IDHwt cases had survivals shorter than the mean.
Average patient survival of this group, however, did not dif-
fer significantly from IDH mutant tumors in this small
cohort.
Recent investigations of the diffuse gliomas have indi-
cated that IDH mutations and 1p/19q co-deletion pro-
vide a framework for defining molecular classes that
distinguish lineages and clinical behavior [11, 41]. Dif-
fuse gliomas with IDH mutations and 1p/19q co-
deletion correspond to oligodendrogliomas, while IDH
mutant tumors lacking the co-deletion typically have
TP53 mutations, ATRX alterations and are considered
astrocytic in differentiation [11, 34, 41]. Diffuse gliomas
that are IDHwt are typically high grade and have clinical
behavior and genetic alterations similar of primary GBM
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[11, 13, 41]. Lastly, grade II and III diffuse gliomas that
contain morphologic features of both oligodendroglioma
and astrocytoma, i.e. oligoastrocytoma, have now been
shown to have either the molecular signature of oligo-
dendroglioma or astrocytoma [44]. Thus, some have
questioned the existence of oligoastrocytoma at the mo-
lecular level [44, 45]. Combining the above molecular-
based approach with morphologic appearance has led to
the use of an “integrated” diagnostic framework. Applied
specifically to tumors diagnosed as GBM-O, recent stud-
ies have shown this diagnostic algorithm separates
GBM-O into prognostically relevant groups, namely ana-
plastic oligodendroglioma and GBM, with the latter fur-
ther classified based on IDH mutation status [36, 46].
The overall patterns of genetic alterations that we have
noted in GBM-O suggest a similar conclusion and indi-
cate that these tumors can be divided into three discrete
molecular classes: 1) those that are IDH mutant and 1p/
19q co-deleted have the molecular signature of a high
grade oligodendroglioma; 2) those that are IDH mutant
and not co-deleted have features of secondary GBM; and
3) those that are IDHwt have the molecular signature of
primary GBMs.
Therefore, despite displaying areas that morphologic-
ally resemble oligodendroglioma, the current findings in-
dicate that these foci do not specifically signify the
presence of 1p/19q co-deletion, and overall lack specifi-
city for a particular genetic signature. Taken together,
the findings suggest molecular testing should be relied
on for establishing diagnoses of diffuse gliomas.
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